Catalyst News and Research

RSS

Catalyst Health Solutions named on 2010 Fortune 100 Fastest-Growing Companies List

Catalyst Health Solutions, Inc., announced today that it was named to the 2010 Fortune 100 Fastest-Growing Companies List. Catalyst has achieved this recognition for three consecutive years and four times in six years. The Company was also named on Fortune's Fastest-Growing All-Stars List.

21 Aug 2010

The Center for Pediatric Dentistry opens in Seattle on September 1, 2010

At today's ribbon cutting ceremony, The Center for Pediatric Dentistry, created to address the growing epidemic of childhood dental disease, announced the grand opening of its facility on September 1, 2010. The Seattle-based institute is the first of its kind in the country, providing pediatric dental care, education for dentists and medical professionals, research, and policy under one roof.

20 Aug 2010

AACR opens nominations for awards recognizing excellence in cancer research

The American Association for Cancer Research is currently accepting nominations for awards recognizing excellence in cancer research, to be presented at the 102nd AACR Annual Meeting 2011, held in Orlando, Fla., from April 2 to 6.

18 Aug 2010

Emerging Healthcare Solutions announces new website of Stand-By Systems

Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems (SBS) has established an Internet presence by launching a website that describes their company and its ground-breaking products. EHSI is currently moving to finalize a Definitive Agreement with SBS and has already executed a term sheet for the deal, which was announced on August 2nd.

17 Aug 2010

Pernix Therapeutics reports decrease in net sales for 2010 second quarter

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the quarter and six months ended June 30, 2010.

17 Aug 2010

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

16 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Catalyst announces $1.5 million registered direct offering

Catalyst Pharmaceutical Partners, Inc. today announced that it has entered into definitive agreements to sell 1,351,352 shares of its common stock at a price per share of $1.11 pursuant to a registered direct offering to two large mutual funds, representing gross proceeds of $1.5 million.

7 Aug 2010

Elsevier Properties congratulates Stewart for achieving Lectureship

Elsevier Properties SA is pleased to congratulate Dr. Scott Stewart on his winning the Royal Australian Chemical Institute's (RACI) 2010/11 Athel Beckwith Lectureship, sponsored by Reaxys.

6 Aug 2010

Catalyst Health Solutions second-quarter 2010 net income up 21%

Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.

5 Aug 2010

ARIAD reports $159.3 million second-quarter net income

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

5 Aug 2010

Pew Prescription Project announces support for new safety legislation

The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The organizations made the announcement in a joint letter to Congress and during an audio news conference with Senator Michael Bennet (D-CO), who will introduce this drug safety legislation.

4 Aug 2010

Emerging Healthcare Solutions executes Term Sheet with Stand-By Systems

Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.

3 Aug 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

Scientists identify new catalytic process to create pharmaceuticals with less chemical waste

Much like two children in the back seat of a car, it can be challenging to get two catalysts to cooperate for the greater good. Now Northwestern University chemists have gotten two catalysts to work together on the same task -- something easily done by nature but a difficult thing to do in the laboratory.The findings, published by the journal Nature Chemistry, will allow medicinal chemists to invent new reactions and produce valuable bioactive compounds faster with less impact on the environment.

29 Jul 2010

Article One completes $5 million institutional funding round with Alleghany Capital

Article One Partners, the world's largest patent research community, today announced the completion of a $5 million round of institutional funding with Alleghany Capital Corporation, a subsidiary of Alleghany Corporation, and other investors. The funding will be used to further consolidate the firm's leading position in the global online patent validation sector by enhancing existing products and services, developing new ones and accelerating sales.

27 Jul 2010

Neurodegenerative disease-causing infectious protein can erupt from healthy brain tissue: Study

In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly erupt from healthy brain tissue.

27 Jul 2010